Affordable Access

Publisher Website

Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function

Molecular and Cellular Endocrinology
Publication Date
DOI: 10.1016/j.mce.2006.04.012
  • Central Precocious Puberty
  • Depot Gnrh Agonist
  • Hyperandrogenism
  • Reproductive Function
  • Ecology
  • Medicine


Abstract Depot gonadotropin releasing hormone (GnRH) agonist (GnRHa) therapy is the treatment of choice for patients with central precocious puberty (CPP). It is still unclear whether long-term exposure to GnRHa is associated with impaired reproductive function in adulthood. The present study was performed on 46 women, former CPP patients, 12.5 ± 3.7 years after the discontinuation of treatment with depot GnRHa. In a structured interview, we assessed general health status, clinical signs possibly associated with hyperandrogenism, menstrual cycle, gynaecological diseases and reproductive function. It appears that long-term treatment with depot GnRHa is safe and does not impair reproductive function. The risk of former CPP patients to develop hirsutism and/or polycystic ovary syndrome does not seem to be increased compared to the normal population but this issue needs to be addressed in further long-term follow-up studies.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Long-term GnRH agonist treatment for female centra...

on Molecular and Cellular Endocri... Jul 25, 2006

Long-term GnRH-agonist treatment does not postpone...

on The Journal of Clinical Endocr... May 1995

Final height in central precocious puberty after l...

on Archives of Disease in Childho... October 1996

Treatment of central precocious puberty by GnRH an...

on Asian journal of andrology July 2008
More articles like this..